<code id='E4B30C3A04'></code><style id='E4B30C3A04'></style>
    • <acronym id='E4B30C3A04'></acronym>
      <center id='E4B30C3A04'><center id='E4B30C3A04'><tfoot id='E4B30C3A04'></tfoot></center><abbr id='E4B30C3A04'><dir id='E4B30C3A04'><tfoot id='E4B30C3A04'></tfoot><noframes id='E4B30C3A04'>

    • <optgroup id='E4B30C3A04'><strike id='E4B30C3A04'><sup id='E4B30C3A04'></sup></strike><code id='E4B30C3A04'></code></optgroup>
        1. <b id='E4B30C3A04'><label id='E4B30C3A04'><select id='E4B30C3A04'><dt id='E4B30C3A04'><span id='E4B30C3A04'></span></dt></select></label></b><u id='E4B30C3A04'></u>
          <i id='E4B30C3A04'><strike id='E4B30C3A04'><tt id='E4B30C3A04'><pre id='E4B30C3A04'></pre></tt></strike></i>

          Home / knowledge / explore

          explore


          explore

          author:fashion    Page View:64
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In